GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,
ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor July 23, 2024 6:45am
Data, along with results from a phase I study, are the first public presentation of VH4524184.
View this post
ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 July 23, 2024 6:39am
Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF showed DTG/3TC demonstrated non-inferior efficacy
View this post
ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024 July 23, 2024 6:32am
Open label extension show maternal and pregnancy outcomes with Apretude exposure were comparable to those with no cabotegravir exposure.
View this post
Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the European Medicines Agency July 19, 2024 2:08am
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
View this post
ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024 July 15, 2024 5:06am
The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options.
View this post
Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria July 5, 2024 5:00am
Launch of single-dose tafenoquine, co-administered with chloroquine, is another step closer to global elimination of malaria.
View this post
Like